Publications

Kircher DA, Trombetti KA, Silvis MR, Parkman GL, Fischer GM, Angel SN, Stehn CM, Strain SC, Grossmann AH, Duffy KL, Boucher KM, McMahon M, Davies MA, Mendoza MC, VanBrocklin MW, Holmen SL (2019). AKT1E17K Activates Focal Adhesion Kinase and Promotes Melanoma Brain Metastasis.(Epub ahead of print) Mol Cancer Res.


Kinsey CG, Camolotto SA, Boespflug AM, Guillen KP, Foth M, Truong A, Schuman SS, Shea JE, Seipp MT, Yap JT, Burrell LD, Lum DH, Whisenant JR, Gilcrease GW 3rd, Cavalieri CC, Rehbein KM, Cutler SL, Affolter KE, Welm AL, Welm BE, Scaife CL, Snyder EL, McMahon M (2019). Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers. Nat Med, 25(4), 620-627.


Rauen KA, Schoyer L, Schill L, Stronach B, Albeck J, Andresen BS, Cave H, Ellis M, Fruchtman SM, Gelb BD, Gibson CC, Gripp K, Hefner E, Huang WYC, Itkin M, Kerr B, Linardic CM,McMahon M, Oberlander B, Perlstein E, Ratner N, Rogers L, Schenck A, Shankar S, Shvartsman S, Stevenson DA, Stites EC, Stork PJS, Sun C, Therrien M, Ullian EM, Widemann BC, Yeh E, Zampino G, Zenker M, Timmer W, McCormick F (2018). Proceedings of the fifth international RASopathies symposium: When development and cancer intersect. Am J Med Genet A, 176(12), 2924-2929.


Mulcahy Levy JM, McMahon M (2018). Linking brain tumors and epileptic seizures. Nat Med,24(11), 1638-1639.


Gardner LJ, Ward M, Andtbacka RHI, Boucher KM, Bowen GM, Bowles TL, Cohen AL,Grossmann K, Hitchcock YJ, Holmen SL, Hyngstrom J, Khong H, McMahon M, Monroe MM, Ross CB, Suneja G, Wada D, Grossman D (2017). Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis. Melanoma Res,27(5), 477-484.


Gardner LJ, Ward M, Andtbacka RHI, Boucher KM, Bowen GM, Bowles TL, Cohen AL,Grossmann K, Hitchcock YJ, Holmen SL, Hyngstrom J, Khong H, McMahon M, Monroe MM, Ross CB, Suneja G, Wada D, Grossman D (10/01/2017). Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis.Melanoma Res, 5477-484.


Silva JM, Deuker MM, Baguley BC, McMahon M (2017). PIK3CA-mutated melanoma cells rely on cooperative signaling through mTORC1/2 for sustained proliferation. Pigment Cell Melanoma Res, 30(3), 353-367.


Sakamoto N, Feng Y, Stolfi C, Kurosu Y, Green M, Lin J, Green ME, Sentani K, Yasui W,McMahon M, Hardiman KM, Spence JR, Horita N, Greenson JK, Kuick R, Cho KR, Fearon ER (2017). BRAF(V600E) cooperates with CDX2 inactivation to promote serrated colorectaltumorigenesis.LID - 10.7554/eLife.20331 [doi]LID - e20331 [pii]. eLife, 6.


Grossauer S, Koeck K, Murphy NE, Meyers ID, Daynac M, Truffaux N, Truong AY, Nicolaides TP, McMahon M, Berger MS, Phillips JJ, James CD, Petritsch CK (2016). Concurrent MEK targeted therapy prevents MAPK pathway reactivation during BRAFV600E targeted inhibition in a novel syngeneic murine glioma model. Oncotarget, 7(46), 75839-75853.


Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, Davies MA, Wargo JA, Curiel-Lewandrowski C, Weber MJ, Leachman SA, Soengas MS, McMahon M, Harbour JW, Swetter SM, Aplin AE, Atkins MB, Bosenberg MW, Dummer R, Gershenwald JE, Halpern AC, Herlyn D, Karakousis GC, Kirkwood JM, Krauthammer M, Lo RS, Long GV, McArthur G, Ribas A, Schuchter L, Sosman JA, Smalley KS, Steeg P, Thomas NE, Tsao H, Tueting T, Weeraratna A, Xu G, Lomax R, Martin A, Silverstein S, Turnham T, Ronai ZA (2016). The state of melanoma: challenges and opportunities. Pigment Cell Melanoma Res, 29(4), 404-16.


van Veen JE, Pringle DR, McMahon M (2016). P2A-Fluorophore Tagging of BRAF Tightly Links Expression to Fluorescence In Vivo. PLoS ONE, 11(6), e0157661.


Deuker et al., (2015) PI3'-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma. Cancer Discovery. 5: 143-153. doi: 10.1158/2159-8290.CD-14-0856


Deuker et al., (2015) PI3'-kinase inhibition forestalls the onset of MEK1/2 inhibitor resistance in BRAF-mutated melanoma. Cancer Discovery. 5: 143-153. doi: 10.1158/2159-8290.CD-14-0856


Shai et al., (2015) TP53 silencing bypasses growth arrest of BRAFV600E-induced lung tumor cells in a two-switch model of lung tumorigenesis. Cancer Research, 75(15): 3167-3180. (doi: 10.1158/0008-5472.CAN-14-3701)


Silva et al., (2014) BRAFV600E cooperates with PI3K signaling, independently of AKT, to regulate melanoma cell proliferation. Molecular Cancer Research, 12(3): 447-463. (doi: 10.1158/1541-7786.MCR-13-0224-T)


Holderfield et al., (2014) Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nature Reviews Cancer, 14:455-467. (doi: 10.1038/nrc3760)


Charles et al., (2014) Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis. Molecular Cancer Research, 12(7): 979-986 (doi: 10.1158/1541-7786.MCR-14-0158-T)


Juan et al., (2014) Diminished WNT->β-catenin->cMYC signaling is a barrier for malignant progression of BRAFV600E-induced lung tumors. Genes & Development, 28: 561-575. (doi: 10.1101/gad.233627.113)


Marsh-Durban et al., (2013) Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma. J. Clin. Invest., 123(12): 5104-5118. (doi: 10.1172/JCI69619)


Trejo et al., (2013) Mutationally activated PIK3CAH1047R cooperates with BRAFV600E to promote lung cancer progression. Cancer Research, 73: 6448-6461. (doi: 10.1158/0008-5472.CAN-13-0681)


Das Thakur et al., (2013) Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature, 494: 251-5. (doi: 10.1038/nature11814)


Collisson et al., (2012) A central role for RAF->MEK->ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discovery, 2: 685-693. (doi: 10.1158/2159-8290.CD-11-0347)


Dankort et al., (2009) BRAFV600E cooperates with Pten loss to induce metastatic melanoma. Nature Genetics, 41: 544-52. (doi: 10.1038/ng.356)


Dankort et al., (2007) A new mouse model to explore the initiation, progression and therapy of BRAFV600E-induced lung tumors. Genes & Development, 21: 379-384. (doi: 10.1101/gad.1516407)

    Principle Investigator
    Martin McMahon, PhD
    Senior Director of Preclinical Translation, Principal Investigator
    martin.mcmahon@hci.utah.edu
    Cancer Center Bio

    Contact Us

    For information on joining our team, contact Karrie.Lasater@hci.utah.edu